Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i- butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral C-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors

Drug Metabolism and Disposition

Volumn 34, Issue 12, 2006, Pages 2028-2035

  Frapolli, R ^a   Marangon, E ^a   Zaffaroni, M ^a   Colombo, T ^a   Falcioni, C ^a   Bagnati, R ^a   Simone, M ^a   D'Incalci, M ^a   Manzotti, C ^b   Fontana, G ^b   Morazzoni, P ^b   Zucchetti, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b INDENA S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

13 (N TERT BUTYLOXYCARBONYL 3 I BUTYLISOSERINOYL) C 7,8 SECO 10 DEACETYLBACCATIN III; 6' MONOHYDROXY [13 (N TERT BUTYLOXYCARBONYL 3 I BUTYLISOSERINOYL) C 7,8 SECO 10 DEACETYLBACCATIN III]; 6'MONOHYDROXY 9 SULFATE [13 (N TERT BUTYLOXYCARBONYL 3 I BUTYLISOSERINOYL) C 7,8 SECO 10 DEACETYLBACCATIN III]; 6,6' DIHYDROXY [13 (N TERT BUTYLOXYCARBONYL 3 I BUTYLISOSERINOYL) C 7,8 SECO 10 DEACETYLBACCATIN III]; 9 SULFATE [13 (N TERT BUTYLOXYCARBONYL 3 I BUTYLISOSERINOYL) C 7,8 SECO 10 DEACETYLBACCATIN III]; DRUG METABOLITE; IDN 5390; PACLITAXEL; POLYSORBATE 80; TAXANE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYCLIZATION; CYTOTOXICITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG URINE LEVEL; FEMALE; FIRST PASS EFFECT; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; BRIDGED COMPOUNDS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FECES; FEMALE; MICE; MICE, INBRED STRAINS; MICROSOMES, LIVER; PACLITAXEL; TAXOIDS; TISSUE DISTRIBUTION;

EID: 33751570159     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.012153     Document Type: Article

References (26)

1. Aisner J and Cortes-Funes H (1997) Paclitaxel in head and neck and other cancers: future prospects. Semin Oncol 24 (Suppl 2):S2-113-S2-115.
2. Appendino G, Danieli B, Jakupovic J., Belloro E, Scambia G, and Bombardelli E (1997) Synthesis and evaluation C-seco paclitaxel analogues. Tetrahedron Lett 16:4273-4276.
3. Bardelmeijer HA, Oomen IA, Hillebrand MJ, Beijnen JH, Schellens JH, and van Tellingen O (2003) Metabolism of paclitaxel in mice. Anticancer Drugs 14:203-209.
4. Bernacki M, Vredenburg M, Kanter P, Pendyala L, Chaudhary N, Mazurchuk R, Morazzoni P, Riva A, and Bombardelli E (2002) IDN-5390, an orally active, antiangiogenic taxoid with low toxicity, ideally suited for metronomic dosing. Eur J Cancer 38 (Suppl 7):S37.
5. Eiseman JL, Eddington ND, Leslie J, MacAuley C, Sentz DL, Zuhowski M, Kujawa JM, Young D, and Egorin MJ (1994) Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 34:465-471.
6. Ferlini C, Raspaglio G, Mozzetti S, Cicchillitti L, Filippetti F, Gallo D, Fattorusso C, Campiani G, and Scambia G (2005) The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res 65:2397-2405.
7. Gupta RS (1983) Taxol resistant mutants of Chinese hamster ovary cells: genetic, biochemical, and cross-resistance studies. J Cell Physiol 114:137-144.
8. Gustafson DL, Long ME, Bradshaw EL, Merz AL, and Kerzic PJ (2005) P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing. Cancer Chemother Pharmacol 56:248-254.
9. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, and Yang CP (1993) Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 15:55-61.
10. Huizing MT, Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, Pinedo HM, and Beijnen JH (1995) Taxanes: a new class of antitumor agents. Cancer Investig 13:381-404.
11. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, and Horwitz SB (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Investig 100:1282-1293.
12. Malingre MM, Beijnen JH, and Schellens JH (2001) Oral delivery of taxanes. Investig New Drugs 19:155-162.
13. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, and Donehower RC (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279.
14. Petrangolini G, Cassinelli G, Pratesi G, Tortoreto M, Favini E, Supino R, Lanzi C, Belluco S, and Zunino F (2004) Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft. Br J Cancer 90:1464-1468.
15. Pratesi G, Laccabue D, Lanzi C, Cassinelli G, Supino R, Zucchetti M, Frapolli R, D'Incalci M, Bombardelli E, Morazzoni P, et al. (2003) IDN 5390: an oral taxane candidate for protracted treatment schedules. Br J Cancer 88:965-972.
16. Rowinsky EK and Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332:1004-1014.
17. Silbergeld DL, Chicoine MR, and Madsen CL (1995) In vitro assessment of Taxol for human glioblastoma: chemosensitivity and cellular locomotion. Anticancer Drugs 6:270-276.
18. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, and van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035.
19. Sparreboom A, van Tellingen O, Nooijen WJ, and Beijnen JH (1996) Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs 7:78-86.
20. Synold TW, Dussault I, and Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584-590.
21. Taraboletti G, Micheletti G, Giavazzi R, and Riva A (2003) IDN 5390: a new concept in taxane development. Anticancer Drugs 14:255-258.
22. Taraboletti G, Micheletti G, Rieppi M, Poli M, Turatto M, Rossi C, Borsotti P, Roccabianca P, Scanziani E, Nicoletti MI, et al. (2002) Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res 8:1182-1188.
23. Terzis AJ, Thorsen F, Heese O, Visted T, Bjerkvig R, Dahl O, Arnold H, and Gundersen G (1997) Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Br J Cancer 75:1744-1752.
24. Verweij J, Clavel M, and Chevalier B (1994) Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 5:495-505.
25. Woo JS, Lee CH, Shim CK, and Hwang SJ (2003) Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res (NY) 20:24-30.
26. Zaffaroni M, Frapolli R, Colombo T, Fruscio R, Bombardelli E, Morazzoni P, Riva A, D'Incalci M, and Zucchetti M (2002) High-performance liquid chromatographic assay for the determination of the novel C-Seco-taxane derivative (IDN 5390) in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 780:93-98.